Background and aim
Results
Thirty studies were eligible for meta-analysis. The MetS OR for HBsAg-positive participants was significantly decreased compared with the controls [OR = 0.80, 95% confidence interval (CI), 0.70-0.90]. The negative effect of HBsAg positivity on elevated triglycerides (OR = 0.62, 95% CI, 0.59-0.64) was strong, while that for increased fasting blood glucose was weak (OR = 0.94, 95% CI, 0.90-0.98). The pooled ORs of central obesity (OR = 0.97, 95% CI, 0.91-1.04), reduced high-density lipoprotein cholesterol (OR = 0.98, 95% CI, 0.83-1.14), and elevated blood pressure (OR = 1.00, 95% CI, 0.80-1.25) for HBsAg-positive participants were all not significantly different compared with the controls. No publication bias was detected. PLOS 
Introduction
Chronic hepatitis B virus (HBV) infection remains a globally challenging problem, as it can lead to chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma [1, 2] . Metabolic syndrome (MetS), characterized by a cluster of metabolic abnormalities including central obesity, increased fasting blood glucose (FBG), increased blood pressure (BP), and dyslipidemia, is another issue of global concern. MetS is a confirmed risk factor for type 2 diabetes mellitus and atherosclerotic cardiovascular disease [3] , and its prevalence has grown rapidly over the past two decades [4] . The liver plays an undeniably important role in lipid and glucose metabolism. MetS involves dyslipidemia and glucose abnormalities. Dyslipidemia is associated with the development of obesity and hypertension, which are also components of MetS. Additionally, nonalcoholic steatohepatitis is considered the hepatic manifestation of MetS [5, 6] , and MetS and nonalcoholic steatohepatitis are mutual promoters [7, 8] . Overall, MetS is related to the liver in some way. The hepatitis virus damages liver function; does it also disrupt the metabolism of lipids and glucose in the liver? Subsequently, does it affect the incidence of MetS?
HBV and hepatitis C virus (HCV) are two common types of hepatitis virus that share some similarities. Chronic HCV infection contributes to MetS, as it induced insulin resistance in a genotype-dependent model [9] . However, the relationship between HBV and MetS in the literature, including large population-based surveys, remains inconclusive. HBV surface antigen (HBsAg) positivity and HBV infection are not synonymous, e.g., there can be occult HBV infection with HBsAg-negative status. Even so, HBsAg positivity is closely related to various HBV infection statuses (HBV carrier, chronic active hepatitis, liver cirrhosis). Consequently, HBsAg is usually an indicator of HBV infection. Some studies [10] [11] [12] [13] [14] concluded that HBsAg seropositivity is a protective factor against MetS, while others [15] [16] [17] have found no association between HBsAg positivity and MetS. These conflicting evidences render a systematic assessment necessary. Unfortunately, the relevant systematic analysis has not been performed. Therefore, we performed this meta-analysis to investigate whether HBsAg seropositivity affects the incidence of MetS and whether HBsAg positivity is related to the components of MetS (central obesity, increased FBG, increased BP, dyslipidemia).
Materials and methods

Search strategy
This meta-analysis was performed according to a proposal for reporting meta-analysis of observational studies [18] . We searched the following databases without time limitations: PubMed, Web of Science, the Cochrane Library. The search strategy for identifying all relevant literature used the following keywords: hepatitis B, metabolic syndrome, hypertension, hyperglycemia, hypertriglyceridemia, dyslipidemia (see S1 Text). The literature search was updated in April 2016.
Study selection
Studies were deemed eligible if they met the following criteria: (1) investigated the association between HBsAg positivity and MetS (including components of MetS: central obesity; increased triglyceride [TG] ; reduced high-density lipoprotein cholesterol [HDL-C]; increased BP; increased FBG). HBV infection was defined as HBsAg seropositivity; (2) used healthy subjects as the control group; (3) included >30 subjects with HBsAg positivity; otherwise, a study was excluded for low statistical power and poor reliability. Exclusion criteria were studies on coinfection, such as human immunodeficiency virus and HBV co-infection, liver cirrhosis, hepatocarcinoma, following antiviral therapy, pregnant or pediatric populations.
Methodological quality assessment and data extraction
Two authors (L.Y.Y. and Z.Y.) independently assessed the quality of eligible studies. The Newcastle-Ottawa Scale criteria [19] were recommended by the Cochrane Collaboration for assessing the quality of nonrandomized studies in a meta-analysis. As it was suitable for case-control and cohort studies, we modified it for cross-sectional studies (Table 1 ). An additional explanation was needed for Q4, which involved the definition of MetS and its components. MetS was defined as the presence of three or more of the following items [4, 20, 21] : (1) elevated waist circumference (WC) (population-and country-specific definitions); (2) elevated TG (!150 mg/dL) or therapy; (3) reduced HDL-C (men, <40 mg/dL; women, <50 mg/dL) or therapy; (4) elevated BP (systolic ! 130 mmHg and/or diastolic ! 85 mmHg) or therapy; (5) elevated FBG or therapy. Elevated FBG was defined slightly differently (!100 mg/dL [20] and !110 Table 1 . Checklist of methodological quality assessment.
Code Checklist
Q1
The participants were recruited from general population, and were not from hospital;
Q2
The subjects with HBsAg positivity and controls were from the same community;
Q3
The experimental group was composed of subjects with HBsAg positivity;
Q4 †
The MetS and its components were defined accurately;
Q5
The same detection method was applied to subjects with HBsAg positivity and controls;
Q6
The same diagnostic criteria were applied to define MetS and its components for subjects with HBsAg positivity and controls;
Q7
The studies list inclusion and exclusion criteria, and patients with hepatitis C virus infection should be excluded at least;
Q8
The studies which were included to calculate combined standardized mean difference were matched for age and sex at least. The studies which were included to calculate combined odds ratio were adjusted for age and sex at least;
Q9
The lifestyle (alcohol and smoking at least) should be considered. The confounding factors from lifestyle were not significantly different between subjects with HBsAg positivity and controls; or they were adjusted in calculating odds ratio.
MetS, metabolic syndrome; HBsAg, hepatitis B surface antigen; mg/dL [21] ). Both were allowable in this meta-analysis, and further subgroup analysis was performed. The checklist of Q4 was that "The MetS and its components were defined accurately". Here, the accurate definition of MetS must meet the above criteria. The accurate definition of a MetS component must match the corresponding item of the MetS component. For example, one study focused only on the relationship between HBsAg positivity and TG (one component of MetS), and the cutoff value for calculating the odds ratio (OR) for elevated TG was identical with the item of MetS (TG ! 150 mg/dL). This study was also awarded one star for Q4. Discrepancies during methodological quality assessment were resolved by consensus agreement. For continuous variables, the mean and standard deviation (SD) of WC, body mass index (BMI), TG, HDL-C, FBG, systolic BP, and diastolic BP for HBsAg positive subjects and the controls were extracted. For categorical variables, the adjusted OR was extracted; otherwise, the crude data were extracted to calculate the OR. In addition, the datasheet included the publication year, region, study design, source of subjects, sample size, mean age, gender distribution, and diagnostic criteria of MetS.
Statistical analysis
The standardized mean difference (SMD) of WC, BMI, TG, HDL-C, FBG, systolic BP, and diastolic BP between the HBsAg-positive group and controls was calculated. Then, the pooled SMD and associated 95% confidence intervals (CI) were obtained from a DerSimonian and Laird random effects model [22] . More importantly, pooled OR was selected to assess the relationship between HBsAg positivity and MetS. Heterogeneity between eligible studies was evaluated by the I 2 test. The degree of heterogeneity was classified to three levels (minimal, I 2 < 25%; moderate, 25% I 2 < 50%; substantial, I 2 ! 50%) [23] . If no significant heterogeneity was detected (P > 0.05 and I 2 < 50%), the fixed effect model was used to calculate the pooled OR and 95% CI. Otherwise, the random effect model was used. To investigate the source of heterogeneity, subgroup analysis and sensitivity analysis was performed according to the factors related to quality assessment. Publication bias was assessed with Egger's test [24] and Begg's test [25] (significance at P < 0.05). Statistical analyses were conducted with Review Manager 5.3 (The Cochrane Collaboration) and STATA 11.0 (Stata Corp., College Station, TX, USA).
Results
Study characteristics
We retrieved 2687 studies using the described search strategies. We excluded 2657 studies in accordance with our inclusion and exclusion criteria (Fig 1) . Ultimately, 30 studies [10] [11] [12] [13] [14] [15] [16] [17] were eligible for this meta-analysis. The MetS and its components were defined accurately) did not affect the statistical results (SMD), so they were labeled with "UR" (unrelated) for Q4 in Table 3 . The remaining 20 studies [10-17, 26-35, 42, 43] reported ORs or crude data for calculating the ORs. The MetS criteria used in these 20 studies was similar, but not identical. S1 Table lists the detailed criteria applied in these 20 studies. Methodological quality assessment Table 3 lists the methodological quality of the studies; the average score of all 30 studies was 7.23. Five studies [11, 34, 39, 40 , 45] did not collect information on HBsAg-positive subjects from the general population, but from patients in the infection department. One study [36] enrolled university graduates as the healthy controls, who were much younger than the HBsAg-positive group. One study [43] did not define the HBsAg-positive group explicitly. The definition criteria of MetS differed slightly in these studies even though most of them were Table) . Five studies involved the distinctive definition of MetS or its components. Jarčuška et al. [16] considered that MetS must present with central obesity. Increased BP was defined as systolic BP ! 140 mmHg or diastolic BP ! 90 mmHg in three studies [13, 27, 42] and as systolic BP ! 135 mmHg or diastolic BP ! 90 mmHg in one study [14] . The Q7, Q8, and Q9 checklists were mainly used to control confounders. Ten studies involved the confounding of HCV. Eleven studies did not control for confounding of age and sex well, while 20 studies did not control for confounding of lifestyle well. Whether these studies [36-41, 44-47] meet Q4 (Q4: MetS and its components were defined accurately) did not affect the statistical results (SMD), so they were labeled "UR" for Q4. The first 20 studies in the table reported OR or crude data for calculating the OR, and the MetS criteria they used affected the statistical results (pooled ORs) directly. Therefore, these studies were carefully investigated to confirm whether they met Q4 (Q4: MetS and its components were defined accurately).
https://doi.org/10.1371/journal.pone.0177713.t003
HBsAg positivity and MetS
Twelve studies [10-17, 28, 30, 32, 33] reported the OR for HBsAg positivity and prevalence of MetS. In all, 610,021 HBsAg-positive subjects and 138,407,811 healthy controls were enrolled in the meta-analysis. The pooled OR for HBsAg positivity and MetS prevalence was 0.80 (95% CI, 0.70-0.90, I 2 = 72%, P < 0.01) (Fig 2) , indicating an inverse association between HBsAg positivity and MetS prevalence. Table 4 lists the subgroup analysis results. The inverse https://doi.org/10.1371/journal.pone.0177713.g002 Table 4 . Results of subgroup analysis according to quality assessments. MetS, metabolic syndrome; WC, waist circumference; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure; FBG, fasting blood glucose.
† Grouped according to checklist of quality assessment (Tables 1 and 3 ). ‡ The data in each grid are the OR (95% CI of OR); the parameters of heterogeneity (I 2 , P-value); the number of included studies. § The studies included for calculating the pooled OR here were not identical to those for calculating the pooled SMD.
For "Elevated TG", the pooled OR was from 14 studies [10] [11] [12] [13] [14] [15] [16] 26 The pooled OR from data adjusted for confounders was 0.73 (95% CI, 0.61-0.88, I 2 = 63%, P = 0.02). This inverse association was also found in the male subgroup (OR = 0.85; 95% CI, 0.74-0.98; I 2 = 64%, P = 0.01), but not in the female subgroup (OR = 0.91; 95% CI, 0.74-1.11; I 2 = 66%, P = 0.008). Furthermore, the heterogeneity did not decrease through subgroup analysis, therefore the specific factor leading to heterogeneity was not found.
HBsAg positivity and central obesity (Fig   3) , indicating that HBsAg positivity is inversely associated with elevated TG. The heterogeneity among the included studies was so low that the subsequent subgroup analysis was omitted. 
HBsAg positivity and reduced HDL-C
Thirteen studies [10-16, 26, 28, 30, 31, 33, 34] involving 605,924 HBsAg-positive subjects and 138,363,354 healthy controls reported the OR for HBsAg positivity and reduced HDL-C. The total OR of the 13 studies was 0.98 (95% CI, 0.83-1.14, I 2 = 85%, P < 0.01) (see S2 Fig) , indicating that HBsAg positivity was not associated with reduced HDL-C. However, the pooled OR of six studies [10, 12-14, 16, 31] that controlled the confounding factors revealed an inverse relationship between HBsAg positivity and reduced HDL-C (OR = 0.88; 95% CI, 0.83-0.94; I 2 = 0%, P = 0.47). The dramatic decrease in heterogeneity was due to adjusting for confounding factors (age, sex at least). However, the dramatic decrease in heterogeneity rendered the results more reliable, the inverse relationship was still weak.
HBsAg positivity and elevated BP
Eleven studies [10-15, 28, 30, 31, 33, 42] reported the OR for HBsAg positivity and elevated BP, and only two [14, 15] reported that HBsAg positivity was associated with increased BP.
The pooled OR of all 11 studies was 1.00 (95% CI, 0.80-1.25; I 2 = 95%, P < 0.001) (see S3 Fig) .
After excluding the two studies [14, 15] , the heterogeneity decreased significantly, and the combined OR from the remaining nine studies [10-13, 28, 30, 31, 33, 42] was 0.94 (95% CI, 0.88-1.01, I 2 = 0%, P = 0.76). The subgroup that included seven studies [10-12, 28, 30, 31, 33] based on ATP III (systolic BP ! 130 mmHg or diastolic BP ! 85 mmHg) also showed no relationship between HBsAg positivity and increased BP (OR = 0.95; 95% CI, 0.88-1.02; I 2 = 0%, P = 0.63). Additionally, similar trends were found in the SMD of systolic BP and diastolic BP.
In conclusion, HBsAg positivity was neither a risk factor nor a protective factor for increased BP, and the difference in BP between HBsAg-positive subjects and healthy controls was not significant.
HBsAg positivity and elevated FBG
Thirteen studies [10-15, 27-31, 33, 34] 
Publication bias
Publication bias was not detected by Egger's test or Begg's test (Table 5 ). For Egger's test, the publication bias 95% CI of each group included zero and P > 0.05, so there was no statistical difference between publication bias and zero, meaning no publication bias was present; Begg's test derived the same conclusion. Taken together, this indicates that there was no publication bias in our meta-analysis.
Discussion
In this meta-analysis, HBsAg-positive individuals had lower prevalence of MetS. This negative association remained robust after adjustment for confounding factors (e.g., age, sex). Meanwhile, a strong inverse relationship was demonstrated between HBsAg positivity and elevated TG (one component of MetS). There was a slight effect of HBsAg positivity on glucose homeostasis. The total OR of all eligible studies indicated no association between HBsAg positivity and reduced HDL-C, but OR controlled for the confounding factors revealed a slight inverse relationship. Additionally, it was confirmed that HBsAg positivity is not associated with central obesity and increased BP. Overall, we speculate that HBsAg positivity protects against the incidence of MetS mainly due to its negative effect on elevated TG. Naturally, further research is required to confirm this. There was a negative association between HBsAg positivity and the prevalence of MetS, and HBsAg positivity is closely related to HBV. HBV may prevent the occurrence of MetS instead of promoting it. That is, HBV may protect humans against MetS. HBV is considered a "metabolovirus", as it adopts a regulatory system that is unique to the major hepatic metabolic genes that control hepatic glucose and lipid metabolism [48] . HBV infection alters bile acid and cholesterol metabolism as a consequence of impaired bile acid uptake [48] . Besides, HBV X protein induces the transcriptional activation of peroxisome proliferator-activated receptor γ (PPARγ) [49] . The activation of PPARγ gene expression during HBV replication boosts the increase in circulating adiponectin levels [50, 51] . Adiponectin has anti-inflammatory effects and protects against insulin resistance. It is inversely associated with BMI, type 2 diabetes mellitus, and several metabolic disorders [51, 52] . Additionally, nonalcoholic steatohepatitis is considered the hepatic manifestation of MetS. A meta-analysis and several large-cohort studies have proven that HBV has a protective effect against the development of hepatic steatosis [6, 53] . The evidence described above all support the inverse relationship between HBsAg positivity and the prevalence of MetS; however, prospective studies are warranted to elucidate the exact mechanism and to validate the inverse relationship.
A recent review [6] has also shown an inverse relationship between HBV and increased TG. The liver is the main organ for lipid metabolism, and hepatic dysfunction such as inflammation, liver fibrosis, cirrhosis, and hepatocellular carcinoma may occur during HBV infection. These processes all influence lipid biosynthesis and metabolism and relate to the change in TG [49] reported that HBV X protein inhibits the secretion of apolipoprotein B. Apolipoprotein B in the liver is an important glycoprotein for the transport of TG-rich very low-density lipoprotein cholesterol and low-density lipoprotein cholesterol. Therefore, HBV X protein increases rapidly upon the active replication of HBV. Then, it inhibits very low-density lipoprotein cholesterol and low-density lipoprotein cholesterol production and promotes TG accumulation in hepatocytes, decreasing TG in the blood. Additionally, increased levels of adiponectin caused by HBV replication reduce serum TG levels and increase HDL-C levels [54] . Besides TG, accumulating evidence has revealed that chronic HBV infection is also inversely associated with other lipid profiles, including cholesterol and low-density lipoprotein cholesterol [6] , and we found a similar trend. In our study, the OR for increased cholesterol from four studies [16, 31, 34, 35] [55] . In short, the possible mechanism for HBsAg positivity with lower TG levels could be related to viral factors and host factors. Furthermore, the weak inverse relationship between HBsAg positivity and reduced HDL-C should be confirmed via further investigation. The inverse relationship between HBsAg positivity and increased FBG was statistically significant, but was weak in the clinic. The relationship between HBV and insulin resistance remains inconclusive and awaits further studies for clarification [6] . However, it is worth pointing out that cirrhosis and poor glycemic control are closely associated [56, 57] . It has been speculated that peripheral insulin clearance is reduced because of cirrhosis, and then insulin resistance and glucose abnormalities occur secondary to hyperinsulinemia [58] .
To the best of our knowledge, this is the first meta-analysis to investigate the relationship between HBsAg positivity and MetS (including its components). Additionally, this meta-analysis was performed rigorously according to a proposal for reporting meta-analysis of observational studies [18] . Although Wang et al. [6] also focused on the association between HBV infection and MetS, theirs was more of an excellent review than a meta-analysis. Second, most of the included studies enrolled >500 subjects, and the large sample size made the conclusion more credible.
There are several limitations to the present meta-analysis. First, the majority of eligible studies were cross-sectional studies, which always demonstrate the least evidence among the three types of observational studies (case-control, cohort, cross-sectional). Additionally, time is an important factor that should be considered, as HBsAg-positive individuals may have different outcomes. Unfortunately, it was difficult to assess the impact of time in this meta-analysis, which we attribute to the cross-sectional nature of the included studies. Second, because only HBsAg was tested and/or it was tested for only once in most of the eligible studies, various conditions related to HBsAg were not taken into account. An HBsAg-positive individual may be a healthy carrier, a patient with chronic active hepatitis, or a patient with liver cirrhosis. Although most studies focused on the general population and most HBsAg-positive subjects may be HBV carriers in this meta-analysis, further stratification of HBsAg status is still needed to assess the exact role of HBsAg in the development of MetS in the future. Third, both age and gender play an important role in the natural history of chronic HBV infection. Unfortunately, the studies included in the subgroup analysis based on these two factors were very limited; however, the negative association between HBsAg passivity and MetS remained robust after adjustment for confounding factors (e.g., age, sex). Fourth, with respect to the definition of MetS, we were not concerned whether drug treatment was an alternate indicator. Finally, we were unsuccessful in obtaining supplemental information from several authors; however, no publication bias was detected.
Our meta-analysis has several implications for future research. First, a prospective largecohort study is needed to validate our conclusion. In this regard, the Newcastle-Ottawa Scale [19] describes the requirements for a rigorous study design and methodology and is a good tool for guiding study design. The unified definition of MetS [4] should be used. As described above, some important factors, such as time, age, gender, and various conditions related to HBsAg, should be taken into account thoroughly in future research. On the other hand, the physiopathological mechanism of the inverse association between HBsAg positivity and MetS requires further research.
In conclusion, serum HBsAg positivity is inversely associated with MetS. Among the five components of MetS, elevated triglycerides had the strongest inverse relationship with HBsAg positivity. 
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